MARKSANS PHARMA LTD.
P&L
Quarterly Consolidated
vs Q2 FY25
Marksans Pharma Reports All-Time High Quarterly PAT of Rs. 105 Cr. in Q3FY25, Driven by 16.3% YoY Revenue Growth
12 Feb 2025 · 12 Feb 2025, 02:19 am
Summary
Marksans Pharma Ltd. reported financial results for the quarter and nine months ended December 31, 2024, with an all-time high quarterly PAT of Rs. 105 cr. The company witnessed robust growth of 16.3% YoY in Q3 revenue, led by the US region which saw 37% YoY growth. Improved product mix and softer raw material prices contributed to gross margin expansion. The company anticipates growth to continue in the coming quarters due to planned new launches and further ramp up of the TEVA facility.
Key Highlights
- 1
Q3 revenue up 16% YoY, leading to an all-time high quarterly PAT of Rs. 105 cr.
- 2
US region witnessed 37% YoY growth, followed by UK with improved performance.
- 3
Gross margin expansion of 279bps YoY to 56.2% due to softening of raw material prices and better product mix.
- 4
Anticipated growth in coming quarters due to planned new launches and further ramp up of the TEVA facility.
- 5
Q3 operating revenue stood at Rs. 681.8 cr., up by 16.3% YoY, and gross profit stood at Rs. 383.5 cr., up by 22.4% YoY.
Management Comments
Mark Saldanha
Managing Director of the Company
We are delighted to announce an all-time high quarterly PAT, driven by robust growth of 16.3% YoY in Q3 revenue. Revenue growth was led by the US region, which witnessed 37% YoY growth, followed by UK, which improved during the quarter. Improved product mix and softer raw material prices compared to the previous year led to gross margin expansion. We witnessed some headwinds in terms of EBITDA margin due to our investments in the acquired facility and increased freight costs during the quarter. Looking ahead, we anticipate growth to continue in the coming quarters augmented by planned new launches and further ramp up of the TEVA facility.
Informational and educational content only. Not investment advice.